ERMN

ERMN encodes Ermin, an oligodendrocyte-specific actin-binding cytoskeletal protein that concentrates at the outer cytoplasmic lip of the myelin sheath and at paranodal loops, where it drives the cytoskeletal rearrangements underlying myelin morphogenesis and maintenance (PMID:16421295). In cultured cells, Ermin localizes to the tips of F-actin-rich processes and its actin-binding domain is required to induce cell protrusions and arborization; deletion of this domain abolishes the morphological activity in both rodent and human orthologs (PMID:16421295, PMID:20934411). Mechanistically, Ermin associates with the myosin phosphatase Rho-interacting protein Mprip/p116RIP and inactivates RhoA, linking it to GTPase-controlled cytoskeletal remodeling in differentiating oligodendrocytes (PMID:32530539). Loss of Ermin produces de-compacted, fragmented, and split myelin, slowed saltatory nerve conduction, motor deficits, inflammatory gliosis, and heightened susceptibility to cuprizone- and immune-mediated (EAE) demyelination, defining Ermin as a maintainer of myelin integrity whose failure can initiate inflammatory dysmyelination (PMID:32530539, PMID:35285112). Ermin immunopositivity tracks active remyelination in both the cuprizone model and human MS lesions (PMID:34437581), and a rare inactivating ERMN mutation has been identified in multiple sclerosis patients, supporting an 'inside-out' model of demyelination driven by intrinsic myelin instability (PMID:35285112). ERMN expression is epigenetically regulated downstream of the TYMS–folate axis during developmental myelination, with folate disruption suppressing ERMN and impairing myelination that is rescued by restoring ERMN or supplementing folate (PMID:31060905).

1. 2006 High

   Establishing what Ermin is and how it acts: identifying it as an oligodendrocyte-specific protein whose actin-binding domain drives cytoskeletal rearrangement answered whether ERMN had a defined cellular function in myelinating cells.

   Evidence Microarray profiling of oligodendrocyte-ablated mice, immunolocalization in nerve and cultured oligodendrocytes, and ectopic expression of wild-type vs. actin-binding-domain-deletion mutants

   PMID:16421295

   Open questions at the time

   • Did not identify direct binding partners beyond F-actin association
   • Mechanism linking actin binding to myelin assembly in vivo not yet defined
2. 2010 Medium

   Confirming that the human ortholog retains the same domain-dependent activity established conservation of Ermin's cytoskeletal effector function across species.

   Evidence Ectopic expression of full-length and truncated human Ermin constructs in COS-7 cells with morphological readout

   PMID:20934411

   Open questions at the time

   • Performed in a non-oligodendrocyte heterologous cell line
   • No identification of binding partners or signaling output
3. 2016 Medium

   Linking ERMN epigenetic regulation to a neurodevelopmental disorder tested whether ERMN dysregulation has disease relevance beyond myelin biology.

   Evidence Genome-wide methylation array, blood RNA-seq, case-control association, and targeted resequencing of ERMN in ASD cohorts

   PMID:27404287

   Open questions at the time

   • No functional experiment connecting methylation changes to protein-level mechanism
   • Association does not establish causality in ASD
4. 2019 High

   Placing ERMN downstream of the TYMS–folate–epigenetic axis explained how environmental and metabolic perturbation suppresses myelination through ERMN.

   Evidence Transcriptomics and methylomics in sevoflurane-exposed macaques and mice, with AAV-mediated ERMN rescue and folic acid supplementation plus cognitive testing

   PMID:31060905

   Open questions at the time

   • Precise epigenetic mark and machinery suppressing ERMN not pinpointed
   • Direct molecular link between ERMN restoration and myelin repair mechanism not resolved
5. 2019 Low

   Correlating reduced ERMN transcript with relapsing-remitting MS provided a peripheral biomarker consistent with its myelin-maintenance role.

   Evidence Quantitative RT-PCR of ERMN in peripheral blood leukocytes of RR-MS patients vs. controls

   PMID:31123898

   Open questions at the time

   • Single-method expression correlation only
   • Peripheral blood may not reflect CNS Ermin biology
   • No mechanistic link to disease causation
6. 2020 High

   Defining the in vivo loss-of-function phenotype and identifying the Mprip/p116RIP–RhoA axis revealed the signaling mechanism by which Ermin maintains myelin.

   Evidence Constitutive Ermn-knockout mice with EM ultrastructure, motor assays, cuprizone demyelination, reciprocal Co-IP with p116RIP, and RhoA activity assays

   PMID:32530539

   Open questions at the time

   • Structural basis of the Ermin–p116RIP interaction unknown
   • How RhoA inactivation is spatially coupled to myelin compaction not resolved
7. 2021 Medium

   Showing Ermin immunopositivity tracks remyelination state established it as an in vivo marker of active myelin repair.

   Evidence Time-course immunohistochemistry in the cuprizone model and immunostaining of MS post-mortem lesions with Ermin, Nogo-A, O4, and O1 markers

   PMID:34437581

   Open questions at the time

   • Correlative marker association, not a functional test of Ermin in remyelination
   • Single-lab study
8. 2021 Low

   Documenting reduced ERMN transcript in ASD peripheral blood, with male-specific significance, reinforced the disease-association signal from the methylation study.

   Evidence Quantitative real-time PCR of ERMN in peripheral blood of ASD patients vs. matched controls

   PMID:34349621

   Open questions at the time

   • Single-method expression data with no protein-level mechanism
   • Peripheral blood relevance to CNS uncertain
9. 2022 High

   Connecting myelin instability to inflammatory activation and human genetic risk supported an 'inside-out' model in which intrinsic Ermin loss initiates demyelinating disease.

   Evidence Ermn-knockout mice with nerve conduction electrophysiology, corpus callosum RNA-seq, gliosis immunohistochemistry, EAE susceptibility, and ERMN sequencing in MS patients

   PMID:35285112

   Open questions at the time

   • Causality of the identified ERMN mutation in MS not functionally proven
   • Mechanism linking myelin decompaction to inflammatory recruitment not detailed

• How Ermin's actin-binding and p116RIP/RhoA signaling are mechanistically coupled to myelin compaction, and how its loss is sensed to trigger neuroinflammation, remains unresolved.
• No structural model of Ermin or its complexes
• Sensor/effector pathway linking myelin instability to gliosis undefined
• Functional validation of human ERMN disease mutations lacking